Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.50 |
| ▸ | FABP7 | O15540 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8516375 | 0.86 | KMT2A (0.54) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL14969483 | 0.84 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL7943600 | 0.83 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL16485222 | 0.83 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL17805715 | 0.83 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29609169 | 0.82 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29608029 | 0.81 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL410205 | 0.81 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL17703893 | 0.81 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL2744229 | 0.81 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109153703-B | Immunomodulator | 百时美施贵宝公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-107223129-B | Immunomodulator | 百时美施贵宝公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-107207568-B | Immunomodulator | 百时美施贵宝公司 | 2021-12-10 | — | — | CN | disclosed |
| EP-3423470-B1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20200291069-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3692053-A1 | IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2020-08-12 | — | — | EP | disclosed |
| CN-111051332-A | Immunomodulator | 百时美施贵宝公司 | 2020-04-21 | — | — | CN | disclosed |
| EP-3626732-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | Bristol-Myers Squibb Company (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-2970390-B1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10450347-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-22 | — | — | US | disclosed |
| WO-2014151634-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20050176649-A1 | Iap binding peptides and assays for identifying compounds that bind iap | NATIONAL INSTITUTES OF HEALTH | 2005-08-11 | — | — | US | disclosed |
| EP-1140895-B1 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-20020183249-A1 | Method of identifying inhibitors of CDC25 | TAYLOR NEIL R (AU) | 2002-12-05 | — | — | US | disclosed |
| WO-2002070680-A1 | METHOD OF IDENTIFYING INHIBITORS OF CDC25 | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-12 | — | — | WO | disclosed |
| EP-1226237-A2 | METHOD OF IDENTIFYING INHIBITORS OF CDC25 | BASF AKTIENGESELLSCHAFT (DE) | 2002-07-31 | — | — | EP | disclosed |
| EP-1140895-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001027077-A2 | HYDROXYSULFONYLALKYLENE-, PHOSPHONOALKYLENE- OR DIFLUORO(PHOSPHONONON)METHYL- SUBSTITUTED BENZENE, OR BENZOFURAN DERIVATIVES AS NON-PEPTIDIC CDC25 INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001016300-A2 | METHOD OF IDENTIFYING INHIBITORS OF CDC25 | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-08 | — | — | WO | disclosed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291069-A1 | IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | KMT2A 2957/4885FABP5 971/4885FABP7 1175/4885 |
| US-20020183249-A1 | Method of identifying inhibitors of CDC25 | CDC25C, CDC25A, CDC25B | KMT2A 4131/4885FABP5 1964/4885FABP7 3463/4885 |
| US-10450347-B2 | Immunomodulators | CD274, PDCD1, PDCD1LG2 | KMT2A 2957/4885FABP5 971/4885FABP7 1175/4885 |
| US-20050176649-A1 | Iap binding peptides and assays for identifying compounds that bind iap | BIRC8, BIRC2, XIAP | KMT2A 4846/4885FABP5 649/4885FABP7 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.